Similar articles for PMID: 23373447

Year	Number of Results
2009	3
2010	5
2011	13
2012	14
2013	15
2014	7
2015	8
2016	10
2017	16
2018	9
2019	12
2020	8
2021	8
2022	8
2023	9
2024	0

1

From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.

Dunn GP, Andronesi OC, Cahill DP. Dunn GP, et al. Neurosurg Focus. 2013 Feb;34(2):E2. doi: 10.3171/2012.12.FOCUS12355. Neurosurg Focus. 2013. PMID: 23373447 Review.

2

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.

Zhang C, Moore LM, Li X, Yung WK, Zhang W. Zhang C, et al. Neuro Oncol. 2013 Sep;15(9):1114-26. doi: 10.1093/neuonc/not087. Epub 2013 Jul 21. Neuro Oncol. 2013. PMID: 23877318 Free PMC article. Review.

3

IDH1 and IDH2 mutations in gliomas.

Cohen AL, Holmen SL, Colman H. Cohen AL, et al. Curr Neurol Neurosci Rep. 2013 May;13(5):345. doi: 10.1007/s11910-013-0345-4. Curr Neurol Neurosci Rep. 2013. PMID: 23532369 Free PMC article. Review.

4

Isocitrate dehydrogenase mutations in gliomas.

Waitkus MS, Diplas BH, Yan H. Waitkus MS, et al. Neuro Oncol. 2016 Jan;18(1):16-26. doi: 10.1093/neuonc/nov136. Epub 2015 Jul 16. Neuro Oncol. 2016. PMID: 26188014 Free PMC article. Review.

5

Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.

Weller M, Wick W, von Deimling A. Weller M, et al. Glia. 2011 Aug;59(8):1200-4. doi: 10.1002/glia.21130. Epub 2011 Feb 3. Glia. 2011. PMID: 21294161 Review.

6

Mutant IDH1 and thrombosis in gliomas.

Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, Chen R, Liu Y, Schwartz MA, Amidei C, Kumthekar P, Benjamin CG, Song K, Dawson C, Rispoli JM, Fatterpekar G, Golfinos JG, Kondziolka D, Karajannis M, Pacione D, Zagzag D, McIntyre T, Snuderl M, Horbinski C. Unruh D, et al. Acta Neuropathol. 2016 Dec;132(6):917-930. doi: 10.1007/s00401-016-1620-7. Epub 2016 Sep 23. Acta Neuropathol. 2016. PMID: 27664011 Free PMC article.

7

Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.

Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D. Juratli TA, et al. Neuro Oncol. 2013 Jun;15(6):682-90. doi: 10.1093/neuonc/not006. Epub 2013 Feb 14. Neuro Oncol. 2013. PMID: 23410661 Free PMC article.

8

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.

Ohba S, Hirose Y. Ohba S, et al. Neurol Med Chir (Tokyo). 2016;56(4):170-9. doi: 10.2176/nmc.ra.2015-0322. Epub 2016 Mar 10. Neurol Med Chir (Tokyo). 2016. PMID: 26960449 Free PMC article. Review.

9

Isocitrate dehydrogenase 1 and 2 mutations in gliomas.

Megova M, Drabek J, Koudelakova V, Trojanec R, Kalita O, Hajduch M. Megova M, et al. J Neurosci Res. 2014 Dec;92(12):1611-20. doi: 10.1002/jnr.23456. Epub 2014 Jul 31. J Neurosci Res. 2014. PMID: 25078896 Review.

10

Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.

Alfaro CM, Pirro V, Keating MF, Hattab EM, Cooks RG, Cohen-Gadol AA. Alfaro CM, et al. J Neurosurg. 2019 Jan 4;132(1):180-187. doi: 10.3171/2018.8.JNS181207. J Neurosurg. 2019. PMID: 30611146

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

123 results

Results by year